Literature DB >> 17613712

Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease.

Gabriele Arendt1, Thorsten Nolting, Christian Frisch, Ingo-Wilhelm Husstedt, Nora Gregor, Eleni Koutsilieri, Mattias Maschke, Alexander Angerer, Mark Obermann, Eva Neuen-Jacob, Ortwin Adams, Sabine Loeffert, Peter Riederer, Volker ter Meulen, Sieghart Sopper.   

Abstract

The objectives of this study is to clarify whether there are phases critical for the infection of the central nervous system (CNS) as defined by active viral replication in the cerebrospinal fluid (CSF) in human immunodeficiency virus (HIV) infection. One hundred and nine HIV-1-positive homo- and bisexual patients in early and late disease stages with or without highly active antiretroviral therapy (HAART) were included in the cross-sectional, diagnostic (phase I) multicenter study. No patients had any overt neurological deficits; all underwent venous and lumbar puncture as well as neuropsychological testing. In untreated early-stage patients, cerebrospinal fluid (CSF) viral load correlated with inflammatory parameters, but not significantly with neuropsychological abnormalities. CSF viral load and inflammatory reactions were suppressed in HAART-treated early-stage patients. In HAART-treated late-stage patients, there was a weak correlation between CSF viral load and CSF cell count as well as a moderate correlation with immune activation markers and with distinct cerebral deficits independent of CSF viral load. Seventeen of the 109 patients had higher CSF than plasma viral loads and marked inflammatory reactions and immune activation. In patients with greater plasma than CSF viral loads, the factors contributing to cerebral deficits still need to be identified. The results suggest not only that there is an early "set point" for CSF/central nervous system (CNS) infection, but also that there is a subgroup of patients in whom intrathecal viral replication correlates with cerebral deficits. Lumbar puncture should be performed in all positive patients to identify members of this subgroup and to ascertain what characteristic factors they have in common in order to improve therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613712     DOI: 10.1080/13550280701315355

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  39 in total

Review 1.  Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system.

Authors:  P Cinque; A Bestetti; P Morelli; S Presi
Journal:  J Neurovirol       Date:  2000-05       Impact factor: 2.643

2.  Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

Authors:  S Staprans; N Marlowe; D Glidden; T Novakovic-Agopian; R M Grant; M Heyes; F Aweeka; S Deeks; R W Price
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

3.  Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication.

Authors:  F García; G Niebla; J Romeu; C Vidal; M Plana; M Ortega; L Ruiz; T Gallart; B Clotet; J M Miró; T Pumarola; J M Gatell
Journal:  AIDS       Date:  1999-08-20       Impact factor: 4.177

4.  Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.

Authors:  S Abdulle; L Hagberg; M Gisslén
Journal:  HIV Med       Date:  2005-05       Impact factor: 3.180

5.  Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease.

Authors:  Hans-Jürgen von Giesen; Ortwin Adams; Hubertus Köller; Gabriele Arendt
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

6.  Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.

Authors:  Andrea De Luca; B C Ciancio; D Larussa; R Murri; A Cingolani; M G Rizzo; M L Giancola; A Ammassari; L Ortona
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

7.  Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.

Authors:  Ronald J Ellis; Meredith E Childers; Joshua D Zimmerman; Simon D W Frost; Reena Deutsch; J Allen McCutchan
Journal:  J Infect Dis       Date:  2003-05-15       Impact factor: 5.226

8.  Comparison of human immunodeficiency virus biological phenotypes isolated from cerebrospinal fluid and peripheral blood.

Authors:  M F Peeters; R L Colebunders; K Van den Abbeele; P C Nys; J Goeman; P Colans; Y Geerts; G Van der Groen
Journal:  J Med Virol       Date:  1995-09       Impact factor: 2.327

9.  Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance.

Authors:  Arabella Bestetti; Silvia Presi; Chiara Pierotti; Simona Bossolasco; Serena Sala; Sara Racca; Paola Carrera; Adriano Lazzarin; Paola Cinque
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

10.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

View more
  9 in total

1.  Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

Authors:  Jose A Muñoz-Moreno; Carmina R Fumaz; Anna Prats; Maria J Ferrer; Eugènia Negredo; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Maite Garolera; Bonaventura Clotet
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

Review 2.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

3.  [Neurological complications of HIV infection].

Authors:  G Arendt; T Nolting
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

4.  Cytokine levels in CSF and neuropsychological performance in HIV patients.

Authors:  Thorsten Nolting; Antje Lindecke; Hans-Peter Hartung; Eleni Koutsilieri; Matthias Maschke; Ingo-W Husstedt; Sieghart Sopper; Olaf Stüve; Gabriele Arendt
Journal:  J Neurovirol       Date:  2012-04-12       Impact factor: 2.643

5.  Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array.

Authors:  Thorsten Nolting; Antje Lindecke; Eleni Koutsilieri; Matthias Maschke; Ingo-W Husstedt; Sieghart Sopper; Olaf Stüve; Hans-Peter Hartung; Gabriele Arendt
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

Review 6.  [Highly active antiretroviral therapy of neuro-AIDS. Side effects on the nervous system and interactions].

Authors:  I W Husstedt; D Reichelt; E Neuen-Jakob; K Hahn; F Kästner; R von Einsiedel; B Vielhaber; G Arendt; S Evers
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

7.  Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV.

Authors:  Mark Obermann; M Küper; O Kastrup; O Yaldizli; S Esser; J Thiermann; E Koutsilieri; G Arendt; H-C Diener; M Maschke
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

8.  The Patient Cohort of the German Competence Network for HIV/AIDS (KompNet): a profile.

Authors:  K Jansen; C Michalik; M Hahn; S Dupke; S Esser; H Jaeger; S Köppe; A Moll; A Plettenberg; R E Schmidt; A Skaletz-Rorowski; N H Brockmeyer
Journal:  Eur J Med Res       Date:  2009-08-12       Impact factor: 2.175

Review 9.  Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier.

Authors:  Nathalie Strazielle; Jean-François Ghersi-Egea
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.